{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:38:13Z","timestamp":1782437893164,"version":"3.54.5"},"reference-count":40,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite advances in T-cell immunotherapy against Epstein-Barr virus (EBV)-infected lymphomas that express the full EBV latency III program, a critical barrier has been that most EBV+ lymphomas express the latency I program, in which the single Epstein-Barr nuclear antigen (EBNA1) is produced. EBNA1 is poorly immunogenic, enabling tumors to evade immune responses. Using a high-throughput screen, we identified decitabine as a potent inducer of immunogenic EBV antigens, including LMP1, EBNA2, and EBNA3C. Induction occurs at low doses and persists after removal of decitabine. Decitabine treatment of latency I EBV+ Burkitt lymphoma (BL) sensitized cells to lysis by EBV-specific cytotoxic T cells (EBV-CTLs). In latency I BL xenografts, decitabine followed by EBV-CTLs results in T-cell homing to tumors and inhibition of tumor growth. Collectively, these results identify key epigenetic factors required for latency restriction and highlight a novel therapeutic approach to sensitize EBV+ lymphomas to immunotherapy.<\/jats:p>","DOI":"10.1182\/blood.2019004126","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T01:59:54Z","timestamp":1583891994000},"page":"1870-1881","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy"],"prefix":"10.1182","volume":"135","author":[{"given":"Tanner","family":"Dalton","sequence":"first","affiliation":[{"name":"Department of Biology, New York University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Doubrovina","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Pankov","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Reynolds","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Scholze","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamalai","family":"Selvakumar","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-9383","authenticated-orcid":false,"given":"Teresa","family":"Vizconde","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumesh","family":"Savalia","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Dyomin","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Weigel","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Oakes","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alonso","sequence":"first","affiliation":[{"name":"Department of Physiology and Biophysics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"first","affiliation":[{"name":"Department of Physiology and Biophysics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-5687","authenticated-orcid":false,"given":"Heng","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Physiology and Biophysics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude M.","family":"Phillip","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"O\u2019Reilly","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Gewurz","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA; and"},{"name":"Department of Microbiology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Cesarman","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Giulino-Roth","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine and"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2020052111212674300_B1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MOH.0000000000000060","article-title":"How do viruses trick B cells into becoming lymphomas?","volume":"21","author":"Cesarman","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"2020052111212674300_B2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","article-title":"EBV-associated lymphoproliferative disorders: classification and treatment","volume":"13","author":"Carbone","year":"2008","journal-title":"Oncologist"},{"issue":"20","key":"2020052111212674300_B3","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"issue":"197","key":"2020052111212674300_B4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A sarcoma involving the jaws in African children","volume":"46","author":"Burkitt","year":"1958","journal-title":"Br J Surg"},{"issue":"6","key":"2020052111212674300_B5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"issue":"20","key":"2020052111212674300_B6","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020052111212674300_B7","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"9331","key":"2020052111212674300_B8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"2020052111212674300_B9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2020052111212674300_B10","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020052111212674300_B11","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.bbmt.2013.12.049","article-title":"Third party donor derived EBV specific T cells for the treatment of refractory EBV-related post-transplant lymphomas","volume":"20","author":"Prockop","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020052111212674300_B12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Pt 10","key":"2020052111212674300_B13","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1099\/vir.0.81906-0","article-title":"Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt\u2019s lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays","volume":"87","author":"Bell","year":"2006","journal-title":"J Gen Virol"},{"issue":"8","key":"2020052111212674300_B14","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin\u2019s disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"issue":"9","key":"2020052111212674300_B15","doi-asserted-by":"crossref","first-page":"e1001114","DOI":"10.1371\/journal.ppat.1001114","article-title":"CpG-methylation regulates a class of Epstein-Barr virus promoters","volume":"6","author":"Bergbauer","year":"2010","journal-title":"PLoS Pathog"},{"issue":"10","key":"2020052111212674300_B16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/ng1424","article-title":"The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome","volume":"36","author":"Bhende","year":"2004","journal-title":"Nat Genet"},{"issue":"1","key":"2020052111212674300_B17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/JVI.06314-11","article-title":"The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites","volume":"86","author":"Kalla","year":"2012","journal-title":"J Virol"},{"issue":"9","key":"2020052111212674300_B18","doi-asserted-by":"crossref","first-page":"e1002902","DOI":"10.1371\/journal.ppat.1002902","article-title":"BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression","volume":"8","author":"Woellmer","year":"2012","journal-title":"PLoS Pathog"},{"issue":"8","key":"2020052111212674300_B19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2004.04.185","article-title":"Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors","volume":"22","author":"Chan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020052111212674300_B20","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1128\/JVI.63.7.3135-3141.1989","article-title":"5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt\u2019s lymphoma line rael","volume":"63","author":"Masucci","year":"1989","journal-title":"J Virol"},{"issue":"1","key":"2020052111212674300_B21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"4","key":"2020052111212674300_B22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF02135399","article-title":"5-Azacytidine, a new, highly effective cancerostatic","volume":"20","author":"Sorm","year":"1964","journal-title":"Experientia"},{"issue":"1","key":"2020052111212674300_B23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"issue":"96","key":"2020052111212674300_B24","first-page":"e52246","article-title":"Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution","author":"Garrett-Bakelman","year":"2015","journal-title":"J Vis Exp"},{"issue":"12","key":"2020052111212674300_B25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nrmicro2015","article-title":"The curious case of the tumour virus: 50 years of Burkitt\u2019s lymphoma [published correction appears in Nat Rev Microbiol. 2009;7(2):172]","volume":"6","author":"Thorley-Lawson","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"2020052111212674300_B26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","article-title":"Regulation of the latent-lytic switch in Epstein-Barr virus","volume":"26","author":"Kenney","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2020052111212674300_B27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"issue":"18","key":"2020052111212674300_B28","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2020052111212674300_B29","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00432-015-1969-3","article-title":"Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma","volume":"141","author":"Stoker","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2020052111212674300_B30","first-page":"449","article-title":"Agents and approaches for lytic induction therapy of Epstein-Barr virus associated malignancies","volume":"6","author":"Novalic","year":"2016","journal-title":"Med Chem (Los Angeles)"},{"issue":"6","key":"2020052111212674300_B31","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2020052111212674300_B32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrmicro3135","article-title":"Keeping it quiet: chromatin control of gammaherpesvirus latency","volume":"11","author":"Lieberman","year":"2013","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"2020052111212674300_B33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chom.2016.04.008","article-title":"Epigenetics and genetics of viral latency","volume":"19","author":"Lieberman","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"20","key":"2020052111212674300_B34","doi-asserted-by":"crossref","first-page":"e00804","DOI":"10.1128\/JVI.00804-17","article-title":"Coordinate regulation of TET2 and EBNA2 controls the DNA methylation state of latent Epstein-Barr virus","volume":"91","author":"Lu","year":"2017","journal-title":"J Virol"},{"issue":"5","key":"2020052111212674300_B35","doi-asserted-by":"crossref","first-page":"e01987","DOI":"10.1128\/JVI.01987-16","article-title":"Restricted TET2 expression in germinal center type B cells promotes stringent Epstein-Barr virus latency","volume":"91","author":"Wille","year":"2017","journal-title":"J Virol"},{"issue":"11","key":"2020052111212674300_B36","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1128\/MCB.15.11.6150","article-title":"Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial","volume":"15","author":"Robertson","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2020052111212674300_B37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nbt805","article-title":"Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes","volume":"21","author":"Koehne","year":"2003","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2020052111212674300_B38","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","article-title":"Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma","volume":"19","author":"Gerdemann","year":"2011","journal-title":"Mol Ther"},{"key":"2020052111212674300_B39","doi-asserted-by":"crossref","first-page":"108632","DOI":"10.1016\/j.biopha.2019.108632","article-title":"Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma","volume":"112","author":"Shi","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2020052111212674300_B40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2017.06.015","article-title":"Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells","volume":"403","author":"Lee","year":"2017","journal-title":"Cancer Lett"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/21\/1870\/1731430\/bloodbld2019004126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/21\/1870\/1731430\/bloodbld2019004126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:23:27Z","timestamp":1590074607000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/21\/1870\/452674\/Epigenetic-reprogramming-sensitizes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,5,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004126","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]}}}